Dynocardia

Executive Summary

Dynocardia is a Boston-based digital health company developing ViTrack™, a wearable platform that enables accurate, continuous, and non-invasive monitoring of blood pressure and other vital heart and lung functions. Founded in 2017 with roots in MIT and Tufts, the company aims to disrupt healthcare by enabling predictive monitoring across hospital, clinical, remote patient monitoring, and consumer wellness markets. Its core technology offers a fundamentally distinct approach from existing monitoring solutions, leveraging advanced sensors and algorithms to provide real-time, cuffless blood pressure measurements. The company is currently in a developmental stage, with no disclosed funding or valuation, but has a clear path to market in the cardiovascular monitoring space, which is rapidly growing due to the shift toward remote care and proactive health management. Dynocardia's differentiation lies in its non-invasive, continuous monitoring capability, which could address unmet needs in hypertension management, postoperative care, and chronic disease tracking. Key upcoming milestones include regulatory clearance and clinical validation studies, which will be critical for commercial traction and investor confidence.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for ViTrack wearable60% success
• Q3 2026Publication of pivotal clinical validation study results70% success
• Q2 2027Strategic partnership with a major healthcare system or remote monitoring platform40% success